Theraclion: More Than One Million German Patients Now Covered For Echotherapy Treatment

Regulatory News:

THERACLION (Paris:ALTHE) (Alternext, FR0010120402 - ALTHE), a company specializing in leading-edge medical equipment for echotherapy, today announces that more than one million Germans are now covered for echotherapy to treat breast fibroadenomas, the most common form of benign breast lesions. Delivered with the Echopulse® System, echotherapy combines high-intensity focused ultrasound (HIFU) and ultrasound imaging to enable accurate, non-invasive treatment of tumors, monitored in real time.

Since September of 2014, three Betriebskrankenkassen (BKK) health insurance companies have subscribed to the coverage plan for echotherapy and two more joined this month, bringing the total to five insurance companies on the contract and more than one million covered patients eligible to receive reimbursed echotherapy treatment in Germany.

Echotherapy is currently available within Germany at Marienhospital in Bottrop and HELIOS Klinik Schkeuditz, both of which have agreements that allow patients to be covered via an integrated care contract. Treatments covered under these agreements have already been delivered earlier this year.

"Our goal is to ensure that all patients who can benefit from echotherapy have access to the treatment,” said David Caumartin, CEO of Theraclion. "We are thrilled to see so many insurance companies throughout Germany signing on to the coverage contract. It’s great news for patients seeking a scarless, outpatient procedure for breast fibroadenomas.”

About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.
Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
Mnemonic: ALTHE - ISIN Code: FR0010120402